Fusion Pharmaceuticals To Present At The 2021 Jefferies London Healthcare Conference
Rhea-AI Summary
Fusion Pharmaceuticals (Nasdaq: FUSN) announces its presentation at the 2021 Jefferies London Healthcare Conference on November 18, 2021, at 8:00 am GMT. Chief Executive Officer John Valliant, Ph.D. will represent the company. A recording will be available for on-demand viewing post-event.
The company develops next-generation radiopharmaceuticals, including its lead program FPI-1434, currently in Phase 1 clinical trials. Fusion also collaborates with AstraZeneca and Merck to advance its innovative therapies.
Positive
- None.
Negative
- None.
News Market Reaction – FUSN
On the day this news was published, FUSN declined 2.41%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
HAMILTON, Ontario and BOSTON, Nov. 11, 2021 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2021 Jefferies London Healthcare Conference. A recording of the presentation will be made available for on-demand viewing on Thursday, November 18, 2021 at 8:00am GMT. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.
A webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.
About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear™ linker technology, Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), advancing to a Phase 1 study following the recent investigational new drug (IND) clearance; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion and Hamilton, Ontario-based McMaster University are building a current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company's growing pipeline of TATs.
View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-2021-jefferies-london-healthcare-conference-301422518.html
SOURCE Fusion Pharmaceuticals Inc.
FAQ
When will Fusion Pharmaceuticals present at the Jefferies London Healthcare Conference?
Who is presenting for Fusion Pharmaceuticals at the conference?
How can I view the presentation for Fusion Pharmaceuticals?
What is the focus of Fusion Pharmaceuticals' clinical research?
What is the status of Fusion Pharmaceuticals' lead program?
Who are Fusion Pharmaceuticals' collaborators in drug development?
